Cargando…

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase

Five‐fluorouracil (5‐FU) is a chemotherapeutic agent that is mainly metabolized by the rate‐limiting enzyme dihydropyrimidine dehydrogenase (DPD). The DPD enzyme activity deficiency involves a wide range of severities. Previous studies have demonstrated the effect of a DPYD single nucleotide polymor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Jihyun, Kim, Andrew HyoungJin, Jeon, Inseung, Oh, Jaeseong, Jang, In‐Jin, Lee, SeungHwan, Cho, Joo‐Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099117/ https://www.ncbi.nlm.nih.gov/pubmed/34863048 http://dx.doi.org/10.1111/cts.13203

Ejemplares similares

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP(®)) Biosimilar, to Those of NESP(®) After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
por: Jeon, Inseung, et al.
Publicado: (2021)

Assessment of Hepatic Cytochrome P450 3A Activity Using Metabolic Markers in Patients with Renal Impairment
por: Kim, Andrew HyoungJin, et al.
Publicado: (2018)

Impact of Vancomycin‐Induced Changes in the Intestinal Microbiota on the Pharmacokinetics of Simvastatin
por: Sunwoo, Jung, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
por: Jin, Xuanyou, et al.
Publicado: (2020)

Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform
por: Kim, Byungwook, et al.
Publicado: (2021)

Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
por: Vogel, Wendy H., et al.
Publicado: (2020)

Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects
por: Jung, Jihyun, et al.
Publicado: (2021)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
por: McLeod, H. L., et al.
Publicado: (1998)

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
por: Ridge, S. A., et al.
Publicado: (1998)

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
por: Donadio, Mauro Daniel Spina, et al.
Publicado: (2022)

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
por: de With, M., et al.
Publicado: (2023)

The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans
por: Oh, Jaeseong, et al.
Publicado: (2017)

Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet
por: Lee, Soyoung, et al.
Publicado: (2018)

Unpredicted Severe Toxicity after 5-Fluorouracil Treatment due to Dihydropyrimidine Dehydrogenase Deficiency
por: Baek, Jin Ho, et al.
Publicado: (2006)

Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer
por: Horiguchi, J, et al.
Publicado: (2002)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

A ferredoxin-dependent dihydropyrimidine dehydrogenase in Clostridium chromiireducens
por: Wang, Feifei, et al.
Publicado: (2020)

Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
por: Royer, B., et al.
Publicado: (2023)

Screening of Dihydropyrimidine Dehydrogenase Genetic Variants by Direct Sequencing in Different Ethnic Groups
por: Shin, Joong-Gon, et al.
Publicado: (2013)

A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity
por: Nagaharu, Keiki, et al.
Publicado: (2016)

Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy
por: Diasio, Robert B., et al.
Publicado: (2022)

Retraction and Republication: A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies
por: Chung, Inbum, et al.
Publicado: (2018)

A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies
por: Chung, Inbum, et al.
Publicado: (2018)

A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies
por: Chung, Inbum, et al.
Publicado: (2017)

In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase
por: Hishinuma, Eiji, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers
por: Henricks, Linda M., et al.
Publicado: (2018)

Single‐dose of LC51‐0255, a selective S1P(1) receptor modulator, showed dose‐dependent and reversible reduction of absolute lymphocyte count in humans
por: Won Lee, Sang, et al.
Publicado: (2022)

Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects
por: Hwang, Inyoung, et al.
Publicado: (2022)

An incidental case of dihydropyrimidine dehydrogenase deficiency: One case, multiple challenges
por: Al Khallaf, Hamoud H., et al.
Publicado: (2013)

Dihydropyrimidine dehydrogenase predicts survival and response to interferon-α in hepatocellular carcinoma
por: Zhu, Wei-Ping, et al.
Publicado: (2018)

Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report
por: Palmirotta, Raffaele, et al.
Publicado: (2019)

Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity
por: Fidai, Shiraz S., et al.
Publicado: (2018)

Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase
por: Merloni, Filippo, et al.
Publicado: (2019)

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
por: Oh, JungJin, et al.
Publicado: (2023)

Comparison of the Plasma Metabolome Profiles Between the Internal Thoracic Artery and Ascending Aorta in Patients Undergoing Coronary Artery Bypass Graft Surgery Using Gas Chromatography Time-of-Flight Mass Spectrometry
por: Kim, Ji Seong, et al.
Publicado: (2019)

The necessary conduct: Exploratory multiregional clinical trials in East Asia
por: Jeon, Inseung, et al.
Publicado: (2021)

Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
por: Jang, Kyungho, et al.
Publicado: (2017)

Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression
por: Jensen, Søren A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_f7h4lckvnfupuo2b42h1pshf0n